| abstract |
The present disclosure relates to a stimulus-responsive nanomaterial, which can be combined with an antigen generated by cryoablation to form a nano in-situ tumor vaccine, can realize the functions of lymph node targeting, in-vivo tumor fragment adsorption, targeted activation of antigen presenting cells, PH response drug controlled release, drug loading, etc., and provides a new method and a new technology for tumor immunotherapy. On one hand, tumor fragments generated by cryoablation retain more antigen information, and an antigen presentation system can be activated more efficiently; on the other hand, the stimulus response type nano material can effectively adsorb tumor fragments and can carry a mode recognition receptor agonist or a drug, so that the capability of targeting and activating antigen presenting cells is enhanced. The stimulus response type nano in-situ tumor vaccine prepared by the method overcomes the defect that the cryoablation kills the far-end focus and the free tumor cells by loading the tumor antigen generated by the cryoablation, and is expected to induce the whole-body immunotherapy while killing the local focus. |